We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




AI-Driven Digital Pathology Diagnostic for Colorectal Cancer Biomarker to Optimize Patient Access to Immunotherapy

By LabMedica International staff writers
Posted on 29 Dec 2023
Print article
Image: AI-generated artistic impression of an H&E-stained whole slide image of cancer tissue (Photo courtesy of Owkin)
Image: AI-generated artistic impression of an H&E-stained whole slide image of cancer tissue (Photo courtesy of Owkin)

Colorectal cancer (CRC), with nearly two million new cases and one million deaths globally in 2020, stands as the third most prevalent cancer worldwide and the second leading cause of cancer-related deaths. A critical genomic biomarker for CRC is Microsatellite Instability (MSI), accounting for approximately 15% of all CRC cases. Recent clinical research underscores the prognostic and therapeutic significance of the MSI phenotype, particularly following the approval of immune checkpoint inhibitor (ICI) therapies. Patients with MSI-positive tumors are often good candidates for ICI therapy, while those with microsatellite stable (MSS) tumors typically are not. Consequently, global consensus guidelines now advocate for MSI testing to guide optimal treatment strategies. Pre-screening instruments that can eliminate the necessity for universal patient testing are emerging as a means to streamline this process and alleviate the burden on laboratory personnel and resources.

A team of scientists from from Owkin, Inc. (Paris, France), in collaboration with French pathology labs has performed a blind validation of MSIntuit CRC, a groundbreaking AI-powered digital pathology diagnostic created by Owkin. Designed as a pre-screening tool, MSIntuit CRC seeks to refine the precision in diagnosing and treating CRC. The tool, leveraging patient-derived data, is crafted to offer reciprocal benefits to patients. The study's findings indicate that MSIntuit CRC can successfully exclude nearly half of the MSS patients while accurately identifying over 96% of MSI patients, in line with the performance of established gold standard methods (92-95%). Such innovations are set to transform the screening process, enabling quicker and more extensive patient screening.

The robustness of the study was evidenced by the blind validation conducted on 600 consecutive CRC cases over two years from nine distinct pathology labs, minimizing the selection bias risk. Additionally, the validation maintained consistent performance across two different pathology slide scanners, with sensitivities of 96% and 98% respectively. The study's focus on sensitivity and specificity as indicators of performance and other methodological strategies underscores the AI model's reliability, ensuring the diagnostic's suitability for clinical use and its applicability across various laboratories and regions.

“With the increasing number of biomarkers to be routinely tested in clinical practice, the need for tools that can both ease bottleneck and resource pressures while ramping up biomarker testing is paramount,” said Meriem Sefta, Chief Diagnostic Officer at Owkin. “Our solution represents the first step towards the development of an AI diagnostic that can identify actionable biomarkers from a single H&E slide used in clinical routine, pushing us closer to realizing a precision medicine future.“

Related Links:
Owkin, Inc. 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Molecular Diagnostics

view channel
Image: Prostate cancer cell image taken using a scanning electron microscope (Photo courtesy of LRI EM Unit)

New Discoveries of Prostate Cancer Evolution Pave Way for Genetic Test

Prostate cancer ranks as one of the most common cancers affecting men, and while it accounts for a significant number of male cancer fatalities, many men live with it rather than die from it.... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Industry

view channel
Image: The companies will develop genetic testing systems based on capillary electrophoresis sequencers (Photo courtesy of 123RF)

Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems

Sysmex Corporation (Kobe, Japan) and Hitachi High-Tech Corporation (Tokyo, Japan) have entered into a collaboration for the development of genetic testing systems using capillary electrophoresis sequencers... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.